LAS VEGAS–As the only pharmacologist to speak at this year’s ACEP conference, Bryan D. Hayes, PharmD, DABAT, FAACT, believes it was “a tremendous testament to the collaborative team work we have in emergency medicine,” he said. The clinical pharmacist at the Massachusetts General Hospital in Boston perhaps initially raised the blood pressure of attendees by posting a highly-technical pharmacology schematic as a joke before turning his focus to two old medications utilized today for major and minor trauma treatment, sedation and pain management.
Tranexamic acid (TXA) has been around for decades. An “antifibrinolytic,” TXA is an anti-clot buster with possible anti-inflammation effects. A randomized, placebo-controlled 2010 trial of 264 hospitals in 40 countries (not including the United States) found that patients who were given TXA had a significantly improved survival rate compared to patients who received the placebo.
“Yet, most trauma bays are still not using TXA,” Mr. Hayes said.